Invion Ltd (IVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Invion Ltd net asset quality index to measure how much of total assets are equity-financed.
Invion Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IVX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Invion Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
|
0.148x |
|
Nanocap Group AB Series B
ST:NANOC-B
|
N/A |
|
Quhuo Ltd
NASDAQ:QH
|
-0.059x |
|
Begbies Traynor Group PLC
LSE:BEG
|
-0.014x |
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
-0.012x |
|
Golden Goliath Resources Ltd.
V:GNG
|
-0.262x |
|
Magnetite Mines Ltd
AU:MGT
|
-0.030x |
|
Silver Castle Holdings Ltd
TA:SLCL
|
0.557x |
Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Invion Ltd (IVX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$8.25 Million ≈ $5.84 Million |
AU$-2.97 Million ≈ $-2.10 Million |
-0.360x | -116.34% |
| 2024-06-30 | AU$14.44 Million ≈ $10.22 Million |
AU$-2.40 Million ≈ $-1.70 Million |
-0.166x | -68.80% |
| 2023-06-30 | AU$18.40 Million ≈ $13.02 Million |
AU$-1.81 Million ≈ $-1.28 Million |
-0.099x | -73.98% |
| 2022-06-30 | AU$19.58 Million ≈ $13.85 Million |
AU$-1.11 Million ≈ $-784.62K |
-0.057x | -164.92% |
| 2021-06-30 | AU$4.79 Million ≈ $3.39 Million |
AU$417.98K ≈ $295.74K |
0.087x | +410.95% |
| 2020-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-152.47K ≈ $-107.88K |
-0.028x | +92.73% |
| 2019-06-30 | AU$5.46 Million ≈ $3.86 Million |
AU$-2.11 Million ≈ $-1.49 Million |
-0.386x | -531.44% |
| 2018-06-30 | AU$7.91 Million ≈ $5.59 Million |
AU$707.09K ≈ $500.31K |
0.089x | +245.01% |
| 2017-06-30 | AU$4.01 Million ≈ $2.84 Million |
AU$-247.14K ≈ $-174.87K |
-0.062x | +90.36% |
| 2016-06-30 | AU$5.99 Million ≈ $4.24 Million |
AU$-3.83 Million ≈ $-2.71 Million |
-0.640x | +56.67% |
| 2015-06-30 | AU$6.86 Million ≈ $4.85 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-1.477x | -244.59% |
| 2014-06-30 | AU$10.16 Million ≈ $7.19 Million |
AU$-4.35 Million ≈ $-3.08 Million |
-0.429x | -36.75% |
| 2013-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-3.46 Million ≈ $-2.45 Million |
-0.313x | +82.26% |
| 2012-06-30 | AU$6.01 Million ≈ $4.25 Million |
AU$-10.62 Million ≈ $-7.51 Million |
-1.766x | -128.12% |
| 2011-06-30 | AU$-2.14 Million ≈ $-1.52 Million |
AU$-13.46 Million ≈ $-9.52 Million |
6.281x | +97.36% |
| 2010-06-30 | AU$-4.78 Million ≈ $-3.38 Million |
AU$-15.20 Million ≈ $-10.76 Million |
3.182x | +4.10% |
| 2008-06-30 | AU$-3.23 Million ≈ $-2.28 Million |
AU$-9.86 Million ≈ $-6.98 Million |
3.057x | +117.84% |
| 2007-06-30 | AU$715.28K ≈ $506.11K |
AU$-12.26 Million ≈ $-8.67 Million |
-17.134x | -597.95% |
| 2006-06-30 | AU$4.83 Million ≈ $3.42 Million |
AU$-11.87 Million ≈ $-8.40 Million |
-2.455x | -- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more